Brief Article
Copyright ©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 7, 2010; 16(45): 5732-5738
Published online Dec 7, 2010. doi: 10.3748/wjg.v16.i45.5732
Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives
Huseyin Demirsoy, Kamil Ozdil, Ozdal Ersoy, Besir Kesici, Cetin Karaca, Canan Alkim, Nihat Akbayir, Levent Kamil Erdem, Mehmet Derya Onuk, Hulya Tugrul Beyzadeoglu
Huseyin Demirsoy, Kamil Ozdil, Ozdal Ersoy, Besir Kesici, Cetin Karaca, Canan Alkim, Nihat Akbayir, Levent Kamil Erdem, Mehmet Derya Onuk, Department of Gastroenterology, Sisli Etfal Training and Research Hospital, 34377 Istanbul, Turkey
Hulya Tugrul Beyzadeoglu, Institute of Hygiene, 34020 Istanbul, Turkey
Author contributions: Demirsoy H, Ozdil K, Kesici B and Ersoy O performed the majority of experiments; Beyzadeoglu HT provided vital reagents and analytical tools and was involved in editing the manuscript; Karaca C, Alkim C, Akbayir N, Erdem LK and Onuk MD co-ordinated and provided the collection of all the human material in addition to providing financial support for this work; Demirsoy H and Ersoy O designed the study and wrote the manuscript.
Correspondence to: Dr. Kamil Ozdil, MD, Department of Gastroenterology, Sisli Etfal Training and Research Hospital, 34377 Istanbul, Turkey. kamilozdil@gmail.com
Telephone: +90-216-4613671 Fax: +90-216-6327124
Received: January 25, 2010
Revised: June 28, 2010
Accepted: July 5, 2010
Published online: December 7, 2010
Abstract

AIM: To identify the role of anti-pancreatic antibody (PAB) in the diagnosis of inflammatory bowel diseases (IBD) among Turkish patients, and its frequency in first-degree relatives.

METHODS: PAB and anti-Saccharomyces cerevisiae (ASCA) were examined in serum samples of 214 subjects including patients with Crohn’s disease (CD, n = 64), ulcerative colitis (UC, n = 63), first-degree relatives of patients with CD (n = 25), first-degree relatives of patients with UC (n = 28),and a control group with gastrointestinal symptoms other than (IBD) (n = 34) by indirect immunofluorescence Positivity of PAB and ASCA was compared in terms of Vienna classification, disease activity and medications used.

RESULTS: In terms of PAB positivity, no difference was found between patients with CD (14.1%) and UC (7.9%) however, significant difference was observed between patients with CD and subjects in the control group (P < 0.05). No difference was found between patients with CD and their relatives in terms of ASCA positivity, whereas a significant difference was found between other groups (P < 0.001). Compared to ASCA, the sensitivity of the PAB was 19% (7/37), its specificity was 93% (25/27), positive predictive value was 77% (7/9) and negative predictive value was 45% (25/55). ASCA was found with significantly higher prevalence in patients with CD activity index > 150 (P < 0.05).

CONCLUSION: PAB is valuable in the diagnosis of IBD rather than CD, but cannot be used alone for diagnostic purposes. PAB is not superior to ASCA in CD diagnosis and in detecting CD among relatives of patients with CD.

Keywords: Anti-pancreatic antibody; Anti-Saccharomyces cerevisiae antibody; Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease